Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Cash from Financing Activities: 2023-2025

Historic Cash from Financing Activities for Zenas BioPharma (ZBIO) over the last 2 years, with Sep 2025 value amounting to $72.6 million.

  • Zenas BioPharma's Cash from Financing Activities fell 68.96% to $72.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.3 million, marking a year-over-year decrease of 81.44%. This contributed to the annual value of $413.0 million for FY2024, which is 1952.88% up from last year.
  • Zenas BioPharma's Cash from Financing Activities amounted to $72.6 million in Q3 2025, which was up 4,116.96% from $1.7 million recorded in Q2 2025.
  • In the past 5 years, Zenas BioPharma's Cash from Financing Activities registered a high of $234.0 million during Q3 2024, and its lowest value of -$614,000 during Q1 2024.
  • Its 3-year average for Cash from Financing Activities is $60.9 million, with a median of $1.8 million in 2024.
  • As far as peak fluctuations go, Zenas BioPharma's Cash from Financing Activities surged by 3,606.00% in 2024, and later slumped by 99.03% in 2025.
  • Zenas BioPharma's Cash from Financing Activities (Quarterly) stood at $50,000 in 2023, then soared by 3,606.00% to $1.9 million in 2024, then crashed by 68.96% to $72.6 million in 2025.
  • Its last three reported values are $72.6 million in Q3 2025, $1.7 million for Q2 2025, and $99,000 during Q1 2025.